Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RCT (n=5040) reports lopinavir–ritonavir (LR) was not associated with reductions in 28-day mortality (374 [23%] patients in LR group vs 767 [22%] usual care group; rate ratio 1.03, 95% CI 0.91–1·.7; p=0.60), duration of hospital stay, invasive mechanical ventilation or death.

SPS commentary:

Authors’ of a related commentary state that compared with the first randomised trial to investigate lopinavir–ritonavir in patients with COVID-19 (by Cao and colleagues), the size of the lopinavir–ritonavir group in the RECOVERY trial was much larger and hence provides a more solid evidence base regarding possible lopinavir–ritonavir treatment effects; and that findings of both these two open-label studies support each other and conclude lopinavir–ritonavir is not effective in improving outcomes for patients admitted to hospital with COVID-19.

The Lancet

Resource links:

Commentary